ArticleFrontiers in bioengineering and biotechnology2026
The value of terahertz three-dimensional tomography for the differential diagnosis of tumor tissue and normal tissue in lung cancer nude mice.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To investigate the value of terahertz (THz) spectroscopy combined with gold nanorods (GNRs) in the differential diagnosis of lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). Methods: Tumor-bearing nude mouse models were established using GNR-treated A549 (LUAD) and NCI-H520 (LUSC) cells. Reflective THz 3D imaging and transmission THz time-domain spectroscopy (THz-TDS) systems, together with CT imaging and pathological validation, were employed to analyze the THz spectral characteristics of Results: CCK-8 and live/dead staining supported the biocompatibility of 40 μg/mL GNRs under the tested conditions. Discussion: Under the tested conditions, GNR treatment was associated with higher THz signals in subcutaneous LUSC and LUAD xenografts. The mechanism and clinical performance remain unestablished; the approach should be regarded as proof-of-concept and as a potential complement to, rather than a replacement for, standard histopathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.